Å
Åke Danielsson
Researcher at Umeå University
Publications - 154
Citations - 9161
Åke Danielsson is an academic researcher from Umeå University. The author has contributed to research in topics: Amylase & Colitis. The author has an hindex of 44, co-authored 154 publications receiving 8729 citations. Previous affiliations of Åke Danielsson include University of Gothenburg & University of Erlangen-Nuremberg.
Papers
More filters
Journal ArticleDOI
Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study
Gunnar Järnerot,Erik Hertervig,Ingalill Friis-Liby,Lars Blomquist,Per Karlén,Christer Grännö,Mogens Vilien,Magnus Ström,Åke Danielsson,Hans Verbaan,Per M. Hellström,Anders Magnuson,Bengt Curman +12 more
TL;DR: Infliximab 4-5 mg/kg is an effective and safe rescue therapy in patients experiencing an acute severe or moderately severe attack of ulcerative colitis not responding to conventional treatment.
Journal ArticleDOI
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Ulrika Broomé,R Olsson,Lars Lööf,G Bodemar,Rolf Hultcrantz,Åke Danielsson,Hanne Prytz,Hanna Sandberg-Gertzén,S Wallerstedt,Greger Lindberg +9 more
TL;DR: It was found that age, serum bilirubin concentration, and histological stage at the time of diagnosis were independent predictors of a bad prognosis, which should be of value for the timing of transplantation and patient counselling in PSC.
Journal ArticleDOI
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.
Annika Bergquist,Anders Ekbom,R Olsson,Dan Kornfeldt,Lars Lööf,Åke Danielsson,Rolf Hultcrantz,Stefan Lindgren,Hanne Prytz,Hanna Sandberg-Gertzén,Sven Almer,Fredrik Granath,Ulrika Broomé +12 more
TL;DR: The frequency of cholangiocarcinoma is 13% and the risk of hepatobiliary carcinoma is constant after the first year after PSC diagnosis with an incidence rate of 1.5% per year, suggestive of an increased risk of pancreatic carcinoma in patients with PSC.
Journal ArticleDOI
Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis
Rolf Olsson,Åke Danielsson,Gunnar Järnerot,Eva Lindstrom,Lars Lööf,Peter Rolny,Bengt-Olof Rydén,Curt Tysk,Sven Wallerstedt +8 more
TL;DR: All patients ≥ 16 years old with a diagnosis of ulcerative colitis were identified in five well-defined catchment areas, representing 12.7% of the Swedish population, giving a point prevalence of 170105 inhabitants.
Journal ArticleDOI
High-dose ursodeoxycholic acid in primary sclerosing cholangitis : a 5-year multicenter, randomized, controlled study.
R Olsson,Kirsten Muri Boberg,Ove Schaffalitsky de Muckadell,Stefan Lindgren,Rolf Hultcrantz,Geir Folvik,Helge Bell,Magnhild Gangsoy-Kristiansen,Jon Matre,Andreas Rydning,Ola Wikman,Åke Danielsson,Hanna Sandberg-Gertzén,Kjell-Arne Ung,Anders Eriksson,Lars Lööf,Hanne Prytz,Hanns-Ulrich Marschall,Ulrika Broomé +18 more
TL;DR: This study found no statistically significant beneficial effect of a higher dose of ursodeoxycholic acid than previously used on survival, symptoms, biochemistry, and quality of life in primary sclerosing cholangitis.